Distribution of evaluable low- and high-sensitivity range samples and of PML-RARα+ samples at 4 INT0129 monitoring-interval checkpoints.
The columns represent the percentage of evaluable samples (ordinate) in the higher-sensitivity range (GAPDH exceeding 2.5 × 106copies; ■) or lower-sensitivity range (GAPDH exceeding 2.5 × 105-2.5 × 106; ░). The percentage of cases that were PML-RARα+ (NQ+) in each sensitivity range at the 4 checkpoints is indicated above each column, while the overall percentage of NQ+ cases is summarized in the last row at the bottom of the Figure. The first row at the bottom of the Figure presents the total number of samples at each checkpoint interval, with the number of PB samples substituted for BM indicated in parentheses. The median number of GAPDH copies and the median NQ for NQ+ cases at each checkpoint interval are indicated in the second and third rows at the bottom of the Figure, respectively. *During the FUP, the median number of samples per patient was 2 (range, 1-8).
